Model LB-200 -Novel Histone Deacetylase Inhibitors (HDACi)

We have also developed another class of compounds that are novel histone deacetylase inhibitors (HDACi). Designated as our LB-200 series of compounds, these have potential use in the prevention and treatment of neurodegenerative diseases. The series has the potential to be the most effective in its class and may be useful for the treatment of chronic hereditary diseases, such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases. LB-200 has not yet advanced to the clinical stage and would require additional capital to fund further development. Accordingly, because of our focus on the clinical development of LB-100 and analogs for cancer therapy, we have decided not to actively pursue the pre-clinical development of the LB-200 series of compounds at this time.